Compare AIHS & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIHS | CDIO |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 5.3M |
| IPO Year | 2018 | N/A |
| Metric | AIHS | CDIO |
|---|---|---|
| Price | $1.30 | $3.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 46.7K | 26.2K |
| Earning Date | 11-19-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,560,626.00 | $15,782.00 |
| Revenue This Year | N/A | $1,434.82 |
| Revenue Next Year | N/A | $4,661.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.83 | $2.42 |
| 52 Week High | $17.00 | $53.10 |
| Indicator | AIHS | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 57.54 |
| Support Level | $1.28 | $2.85 |
| Resistance Level | $1.43 | $3.13 |
| Average True Range (ATR) | 0.13 | 0.35 |
| MACD | 0.05 | 0.08 |
| Stochastic Oscillator | 70.21 | 100.00 |
Senmiao Technology Ltd is a holding company. Along with its subsidiaries, it is engaged in facilitating automobile transactions and offering related services. The group's business activities include providing car rental services to individual customers with lease term no more than twelve months; leasing and servicing of new energy vehicles; offering services to automobile purchasers throughout the purchase process; providing management and related services to Partner Platforms and other companies; automobile financing; and providing other related supporting services to customers. The majority of the group's revenue is generated from its automobile rental business.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.